Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T08:31:30.448Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders

Published online by Cambridge University Press:  09 April 2020

Kai Zhang Open the ORCID record for Kai Zhang [Opens in a new window] ,
Xiaoqin Zhou ,
Huanzhong Liu  and
Kenji Hashimoto Open the ORCID record for Kenji Hashimoto [Opens in a new window]
Kai Zhang*
Affiliation:
Department of Psychiatry, Chaohu Hospital, Anhui Medical University, China
Xiaoqin Zhou
Affiliation:
Department of Psychiatry, Chaohu Hospital, Anhui Medical University, China
Huanzhong Liu
Affiliation:
Department of Psychiatry, Chaohu Hospital, Anhui Medical University, China
Kenji Hashimoto
Affiliation:
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Japan
*
Correspondence: Kai Zhang. Email: [email protected]
Rights & Permissions [Opens in a new window]

Summary

Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.

Keywords

Antipsychoticsantiviralpsychotic disorderscoronavirusdrug interactions and side-effects
Type
Editorial
Information
The British Journal of Psychiatry , Volume 217 , Issue 1 , July 2020 , pp. 351
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

Since December 2019, the novel coronavirus disease 2019 (COVID-19) has spread from Wuhan to other cities in China and around the world, including Japan.Reference Wang, Horby, Hayden and Gao1 As of 17 February 2020, there have been 70 673 confirmed cases in China. The National Health Commission of China (NHCC) has published guidelines for treatment of COVID-19. Recommended antiviral drugs by the NHCC include interferon-α, lopinavir/ritonavir and ribavirin.2

As psychiatrists, we are particularly concerned about two aspects of this situation. First, many patients with psychiatric disorders have been infected with COVID-19, and second, patients with COVID-19 infections may develop a number of psychiatric symptoms, including anxiety, fear, depression and insomnia, after treatment with antiviral drugs. This is concerning because Wuhan Mental Health Center, the largest psychiatric hospital in Hubei province, reports that more than 80 staff and patients have been infected with COVID-19.Reference Wu3

If a patient with psychiatric disorder is infected with COVID-19, antiviral drugs must be used in combination with psychotropic drugs, including antipsychotic, antidepressant and antianxiety drugs. If antiviral drugs are used without supplemental medication, patients with psychiatric disorders can experience relapses in their mental illness. Importantly, patients may present with impulsivity, running or other abnormal behaviours that are not conducive to the control of COVID-19. Psychotropic medications are thus necessary to avoid these and other behavioural problems. The most pressing question for doctors on the front line is how to choose the appropriate psychotropic drug in combination with the antivirals recommended by the NHCC.

The combination of antivirals and psychotropic drugs should be considered in the context of potential drug–drug interactions. Most antipsychotic drugs and antiviral medications utilise cytochrome P450 (CYP) enzymes for their metabolism.Reference Roncero, Villegas, Martinez-Rebollar and Buti4 Anxiety, nervousness, insomnia and other symptoms can occur in patients with COVID-19 because of stressor events. Because sedative and hypnotic drugs such as oxazepam and lorazepam are not metabolised by the CYP system, these are quite safe when used in combination with the recommended antiviral drugs.

Given the tolerability and minimal P450 interactions, antidepressants (citalopram, escitalopram, etc.), antipsychotics (olanzapine) and valproate can be considered to be safe in combination with antiviral drugs. Special care should be taken to ensure that drug–drug interactions are prevented when psychotropic drugs are used in combination with antivirals.

Author contributions

K.Z. and K.H. conceived of the presented idea. K.Z. wrote the manuscript. X.Z., H.L. and K.H. revised the manuscript. All authors discussed and contributed to the final manuscript.

Declaration of interest

None.

ICMJE forms are in the supplementary material, available online at https://doi.org/10.1192/bjp.2020.84.

References

Wang, C, Horby, PW, Hayden, FG, Gao, GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470–3.CrossRefGoogle ScholarPubMed
National Health Commission of the People's Republic of China (NHCC). Diagnosis and Treatment Guideline of COVID-19 (Version 5). NHCC, 2020 (http://www.gov.cn/zhengce/zhengceku/2020-02/09/content_5476407.htm).Google Scholar
Wu, XY. About 80 doctors and patients at the Wuhan Mental Health Center were diagnosed with COVID-19. China News Weekly, 2020 (http://society.people.com.cn/n1/2020/0209/c1008-31577664.html).Google Scholar
Roncero, C, Villegas, JL, Martinez-Rebollar, M, Buti, M. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis C and psychotropic drugs. Expert Rev Clin Pharmacol 2018; 11(10): 999–1030.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Zhang et al. supplementary material

Zhang et al. supplementary material

Download Zhang et al. supplementary material(PDF)
PDF 1.3 MB
Submit a response

eLetters

No eLetters have been published for this article.